The main risk of developing cervical cancer is the persistence of an High risk human papillomavirus (HPV-HR) infection, the mechanisms of which are still not understood. These chronically infected patients could develop multi-site lesions. The main objective is to assess the feasibility of setting up a personalized screening in patients at high risk of cervical cancer (chronically infected with HPV), by evaluating documenting the acceptability of these patients to be sampled from the ENT sphere and anal spheres for HPV analysis with next-generation sequencing.
Patients who have given their written consent to participate in the study.
Person affiliated or beneficiary of a social security scheme.
None
Single group
Smear
Procedure/SurgeryIn addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
Acceptance by the patient (yes / no binary variable) of ENT and / or anal samples in addition to the cervical sample during an annual gynecological follow-up.
Number of sites sampled
It will be collected anonymously if spontaneously explained by the patient.
Reasons for refusing multi-site samples
Positivity to HPV tests for at least one of the other sites (ENT or anal)
Identification of HPV + subtypes on the different sites
Click on the lead sponsor to view all of their trials.
